Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Inge Marie Svane
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07501117CT.gov Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | — | Not Yet Recruiting | — | — | — |
NCT06581406CT.gov A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
NCT06519266CT.gov PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases | — | Recruiting | — | — | — |
NCT05987332CT.gov IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | — | Active Not Recruiting | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05004025CT.gov Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | — | Completed | — | — | — |
NCT04935229CT.gov Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | — | Terminated | — | — | — |
NCT04463368CT.gov Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases | — | Completed | — | — | — |
NCT04552223CT.gov Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | — | Completed | — | — | — |
NCT04283890CT.gov PHP and Immunotherapy in Metastasized UM | — | Active Not Recruiting | — | — | — |
Show 8 more trialsShow fewer
NCT03922880CT.gov Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | — | Completed | — | — | — |
NCT03472586CT.gov Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | — | Completed | — | — | — |
NCT03326258CT.gov Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | — | Withdrawn | — | — | — |
NCT02831933CT.gov Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma | — | Terminated | — | — | — |
NCT02913417CT.gov Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | — | Unknown | — | — | — |
NCT02626962CT.gov Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | — | Completed | — | — | — |
NCT02519322CT.gov Neoadjuvant and Adjuvant Checkpoint Blockade | — | Completed | — | — | — |
NCT01585194CT.gov Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Inge Marie Svane | P3 | BB · 65 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →